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Summary 
An individual patient meta-analysis was performed on the gametocytocidal and transmission-
blocking activities of single dose primaquine. Gametocyte persistence and infectivity depended on 
the artemisinin-combination therapy that primaquine was administered with. Primaquine’s 
transmission-blocking effects were achieved at 0.25 mg /kg.  
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article/doi/10.1093/infdis/jiaa498/5890806 by guest on 17 August 2020
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
Abstract 
Background  
Since the World Health Organization recommended single low-dose (0.25mg/kg) primaquine (PQ) in 
combination with artemisinin-based combination therapies (ACTs) in areas of low transmission or 
artemisinin-resistant P. falciparum, several single-site studies have been conducted to assess its 
efficacy.  
Methods 
An individual patient meta-analysis to assess the gametocytocidal and transmission-blocking efficacy 
of PQ used in combination with different ACTs was conducted. Random effects logistic regression 
was used to quantify PQ effect on (i) gametocyte carriage in the first two weeks post-treatment;  (ii) 
the probability of infecting at least one mosquito or of a mosquito becoming infected.  
Results 
In  2,574 participants from fourteen studies, PQ reduced PCR-determined gametocyte carriage on 
days 7 and 14, most apparently in patients presenting with gametocytaemia on day 0 (Odds Ratio 
(OR)=0.22; 95%CI 0.17-0.28 and OR=0.12; 95%CI 0.08–0.16, respectively). The rate of decline in 
gametocyte carriage was faster when PQ was combined with artemether-lumefantrine (AL) 
compared to dihydroartemisinin-piperaquine (DP) (p=0.010 for day 7). Addition of 0.25mg/kg PQ 
was associated with near complete prevention of transmission to mosquitoes. 
Conclusion 
Primaquine’s transmission-blocking effects are achieved with 0.25 mg/kg PQ. Gametocyte 
persistence and infectivity are lower when PQ is combined with AL compared to DP.  
 
Keywords:   Single low dose primaquine, Plasmodium falciparum, Gametocytaemia 
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Background 
Antimalarial regimens based on artemisinin and its derivatives, artemisinin-based combination 
therapies (ACTs) have been adopted widely as first line treatment of uncomplicated malaria.  
Despite highly efficient clearance of asexual stage parasites and early gametocytes [1, 2], ACTs do 
not affect mature Plasmodium falciparum gametocytes. Mature gametocytes are responsible for 
transmission of infection from humans to mosquitoes, and they remain largely unaffected by 
antimalarial treatment, including ACTs [3-5]. As a result, gametocyte carriage can persist for several 
days and even weeks after ACT administration [3, 6] and treated individuals can continue to be a 
source of mosquito infections [3, 7, 8]. As malaria control programs focus their efforts on regional 
elimination and global eradication and the necessity to contain drug resistant parasites, targeting 
gametocytes as part of routine clinical care and community treatment campaigns is being 
recommended [9-11]. 
Primaquine (PQ), a drug that is used routinely for the radical cure of Plasmodium vivax and ovale 
infections, has been recast as a viable treatment strategy to reduce P. falciparum transmission. The 
ability of PQ and its predecessor plasmoquine to stop P. falciparum infectivity to malaria vectors has 
been known for many decades [12, 13]. In 2012, the World Health Organization (WHO) 
recommended the use of PQ, in combination with ACTs, in areas approaching elimination and where 
artemisinin-resistance was observed [10]. To mitigate concerns related to haemolysis in individuals 
with glucose-6-phosphate dehydrogenase deficiency (G6PDd) and based on efficacy shown at low 
doses, a single low-dose of 0.25mg/kg of PQ was recommended for the gametocytocidal indication 
[10]. The safety of single low-dose PQ was confirmed in subsequent safety studies in individuals with 
G6PDd [14, 15]. Multiple efficacy studies have been conducted to determine the gametocytocidal 
and transmission-blocking activity of PQ at different doses and with different partner ACTs. 
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We conducted a systematic review and individual patient data (IPD) meta-analysis of clinical trials to 
quantify the ability of single-dose PQ given in combination with different ACTs to clear gametocytes 
and block transmission, and to compare efficacies of different combinations.  
 
Methods 
Data pooling 
Details of the systematic review (PROSPERO CRD42019126710) are provided in Supplementary File 
1.  Studies were eligible for the inclusion in this analysis if (i) IPD came from a clinical efficacy trial of 
patients with uncomplicated P. falciparum infection or asymptomatic parasite carriers containing at 
least one study arm with a combination of a blood schizonticide and a single dose of PQ; (ii) patient 
demographics and information on dosing (mg/kg) of the blood schizonticide and PQ were available; 
(iii) transmission potential was assessed by weekly gametocyte carriage (i.e. prevalence) using 
molecular methods and/or by membrane feeding assay conducted on day 0 and any day post-
treatment; (iv) patients were followed up at least until day 14. In the eligible studies, non-ACT study 
arms, which were randomised to receive PQ or not, were also included in the analysis as they 
contributed to the overall estimate of PQ effect.   
Statistical Analysis 
Statistical analyses were carried out according to an a priori statistical analysis plan [16]. The 
prevalence of gametocytaemia on days 7 and 14 after first administration of any treatment (day 0) 
was determined seperately for patients without and with  gametocytes on enrollment. Logistic 
regression models for gametocyte prevalence (0/1), as measured by molecular methods 
(quantitative reverse-transcriptase-PCR (qRT-PCR) or quantitative nucleid acid sequence based 
amplification (QT-NASBA)), on each day were fitted with random intercepts for study site.  
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Data from membrane feeding experiments were analysed using logistic regression to identify 
predictors of (a) probability of a participant infecting at least one mosquito; (b) probability of a 
feeding mosquito being infected. Random intercepts were included to account for multiple 
measurements per patient (a) or clustering within a membrane feeding experiment (b).   
Additional details such as predictors considered in each of the regression models and assessment of 
risk of bias analysis are given in Supplementary File 1. 
 
Results 
The systematic review identified 13 studies eligible for inclusion and two additional studies were 
identified in response to the call for data (Supplementary Figure 1). IPD from fourteen studies were 
shared; their details are presented in Supplementary Table 1. Five studies used QT-NASBA (including 
two where quantification was not performed), eight used qRT-PCR and one study used both. The 
target transcripts in these molecular assays included Pfs25, Pfs230p and Pfg377 mRNA. In addition 
to sexual-stage specific parasite detection, three of these studies also included data from membrane 
feeding experiments, where infectiousness was directly quantified by feeding mosquitoes on 
infected blood and assessing oocyst development one week later. G6PD deficiency was assessed 
using fluorescence spot test (FST) in four studies, rapid diagnostic test (RDT) in five studies, or 
genotyping in three studies. All studies, except one from Colombia, were conducted in Africa at sites 
with varying transmission intensities. Administration of PQ was randomised and compared to a no-
PQ arm in all studies except for one in which the dose of PQ was increased sequentially (Study ID 8). 
A total of 66.7% (1,718/2,574) of participants received a dose of PQ (25.0%–100.0% in individual 
studies), of whom 355 (20.7%) were treated on day 0, 1241 (72.2%) on day 2 and 122 (7.1%) on day 
3. Of the 1718 individuals treated with PQ, 477 (27.8%) patients received the WHO-recommended 
0.25mg/kg dose and 474 (27.6%) received a 0.40mg/kg dose. Other doses tested included 0.0625, 
0.1, 0.125, 0.2, 0.50 and 0.75mg/kg (Table 1).   
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The median age of study participants was 9 years (interquartile range IQR 5-14) with 19.7% 
(504/2,563) below 5 years of age. Most of the 2,574 study participants were treated with 
artemether-lumefantrine (AL) (1,278; 49.7%) or dihydroartemisinin-piperaquine (DP) (1,044; 40.7%). 
Other treatments administered included: artesunate-sulfadoxine-pyrimethamine (ASSP) (212; 8.3%) 
and sulfadoxine-pyrimethamine-amodiaquine (SPAQ) (40; 1.6%). At enrolment, 14.5% (366/2,525) of 
patients presented with anaemia (haemoglobin level below 10.0g/dL), 12.8% (239/1,860) with fever, 
and 5.8% (139/2,392) had more than 100,000 parasites/µL (Table 1); 12.2% (59/484) of the children 
<5 years of age were underweight (weight-for-age z-score<-2). The proportion of participants with 
fever at enrolment was lower in the group of individuals receiving PQ compared to the group that 
did not receive PQ (9.9% versus 18.2% respectively); however, the difference was not significant 
after adjusting for study site (p=0.966). Six studies’ protocols excluded individuals with G6PDd 
(Supplementary Table 1). 
 
Gametocytaemia after treatment in participants with no detectable gametocytes at baseline  
In total, 632 (31.3%) patients presented without detectable gametocytes on enrolment, of whom 
481 (76.1%) were assessed weekly for gametocyte carriage during the first 14 days of follow-up. 
Detectable post-treatment gametocytaemia was present in 12.9% (39/302) of patients treated with 
PQ compared to 19.6% (35/179) of those not treated with PQ (Odds Ratio OR= 0.55; 95%CI 0.32- 
0.96; p=0.035, adjusted for study-site random effect) (Supplementary Table 2). The effect of PQ on 
gametocyte appearance was similar (p=0.308) between day 7 (OR=0.58; 95%CI 0.33-1.01; p=0.053) 
and day 14 (OR=0.30; 95%CI 0.14–0.63; p=0.002)  
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Gametocytaemia after treatment in participants with gametocytes at baseline 
At enrolment, 1,754 (68.7%) patients had gametocytes detected by molecular methods. Among 
those patients treated with PQ, 23.4% (258/1,101) had gametocytes detected on day 7 compared to 
57.4% (316/551) of those not treated with PQ (OR=0.22; 95%CI 0.17-0.28; p<0.001). The 
corresponding proportions of individuals who were still gametocytaemic on day 14 were 11.4% 
(106/931) and 42.9% (202/471) respectively (OR=0.12; 95%CI 0.08–0.16; p<0.001); (Supplementary 
Table 2, Figure 1). In multivariable mixed effects models, gametocyte positivity on day 7 was 
associated significantly with gametocyte and asexual parasite densities and haemoglobin 
concentration at baseline (Table 2). Compared to patients treated with DP, those treated with AL 
were significantly less likely to have gametocytes on Day 7 (AOR=0.50; 95%CI 0.28–0.90; p=0.021), 
while those treated with SPAQ were more likely to carry gametocytes (AOR=16.16; 95%CI 1.88–139; 
p=0.011). On day 14, only the baseline gametocyte density and antimalarial treatment were 
correlated with gametocyte carriage. After adjustment for these factors, a higher dose of PQ was 
associated with lower prevalence of gametocyte positivity on days 7 and 14 (AOR= 0.69; 95%CI 0.65-
0.74 and AOR=0.58; 95%CI 0.53-0.64 for each 0.1 mg per kg increase in dose respectively, both 
p<0.001).   This dose effect translates to an AOR (95% CI) of 0.40 (0.34-0.46) for day 7 gametocyte 
carriage and 0.26 (0.20–0.33) for day 14 gametocyte carriage for patients who received 0.25mg/kg 
dose of PQ compared to those who did not receive PQ. 
A fractional polynomial model was used to estimate the probability of gametocyte carriage on days 7 
and 14 for 1,543 individuals receiving different PQ doses with AL or DP (Figure 2). Whilst addition of 
PQ reduced gametocyte carriage for both ACTs, the rate of decline in gametocyte carriage associated 
with PQ dose differed between patients treated with AL and DP (test for interaction: p=0.010 for day 
7 and p <0.001 for day 14). Among individuals treated with AL, most of the reduction in gametocyte 
carriage probability was achieved with the recommended 0.25mg/kg PQ dose, whereas in individuals 
treated with DP higher doses of PQ were associated with additional substantial reductions in 
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gametocyte carriage.  Administration of a PQ dose of 0.25mg/kg in patients treated with AL reduced 
risk of gametocytaemia on Day 7 to 26.0% (95%CI 18.7-34.9)  and on Day 14 to 7.6% (95%CI  4.3-
13.2)  compared to 37.1% (95%CI 27.6–47.8) and 18.2% (95%CI 11.4-27.9) in patients treated with 
DP, respectively.    
The risk for gametocyte carriage was significantly higher on day 7 in patients treated with PQ on day 
2 or 3 compared to patients treated with PQ on day 0 (AOR=2.28; 95%CI 1.66-3.69, p<0.001, 
adjusted for covariates in the main analysis, Table 2). However, this difference was not significant by 
day 14 (AOR=1.74; 95%CI 0.80-3.81, p=0.164, adjusted for covariates in the main analysis, Table 2). 
Administration of PQ also reduced gametocyte density in those positive on days 7 or 14. Expressed 
as a proportion of the baseline gametocyte density, gametocyte densities reached median values 
(IQR) of 2.0% (0.3–10.2%) relative to baseline by day 7 in PQ-treated individuals compared to 29.8% 
(8.1-77.4) in individuals who did not receive PQ (p<0.001 Wald test, adjusted for ACT and study). The 
corresponding values on day 14 were 0.5% (0.1–5.6) in PQ-treated individuals and 9.6% (1.5–36.0) in 
individuals who did not receive PQ (p<0.001, Wald test adjusted for ACT and study). 
 
Mosquito feeding assays 
 In the three studies undertaking mosquito feeding experiments (Supplementary Tables 1 and 3), 
participants were treated with either AL (1 study), DP (2 studies) or SPAQ (1 study) and a PQ dose of 
0.25mg/kg was compared to ACT alone in all studies. In one of these studies, the 0.40mg/kg dose 
was tested, and in another study, PQ doses of 0.0625, 0.125 and 0.50mg/kg were also administered. 
These data are presented in Supplementary Table 4. 
Among 316 feeding experiments conducted prior to treatment on participants with baseline 
gametocytaemia, 186 (58.9%) infected at least one mosquito, with a median of 13.9.0% (range 1.2%-
96.5%) of mosquitoes infected (Figure 3, Supplementary Table 4). While the proportion of the 
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infected mosquitoes (in infectious feeds) was similar between the three studies (p=0.369), the 
number of non-infectious feeds ranged from 37.8-67.9% (p<0.001) between studies, with the lowest 
proportion observed in study ID 6 (AL/AL+PQ). This study had the lowest baseline gametocytes 
levels; 79.0% of patients had fewer than 50 gametocytes/µL compared to 24.7% and 42.5% in the 
other 2 studies. 
In patients with confirmed gametocytaemia at baseline and at the time of sampling post treatment, 
13.2% of feeds (36/272) of those treated with PQ infected at least one mosquito, compared to 35.6% 
(63/177) of non-PQ treated patients sampled at the same timepoints (Figure 3, Supplementary 
Table 4).  There were significant differences between studies/treatments: among patients who did 
not receive PQ, only one feed (1/61, 1.6%; days tested 3,7,10,14) infected any mosquitoes after AL 
compared to 49.4% (39/79; days tested 1,2,7) for DP and 59.0% (23/39; days tested 1,2,6,7,8) for 
SPAQ.  In the PQ arms, the proportion of feeds that infected any mosquitoes was 0.0% (0/83) with 
AL, 2.6% (1/38) with SPAQ and 22.2% (35/158) with DP. From day 5 after PQ administration, of 283 
feeds only 2 feeds were infectious, both in DP arms with PQ doses of 0.0625 and 0.5mg/kg. 
The risk of a participant infecting at least one mosquito and the risk of a feeding mosquito becoming 
infected were strongly associa ed with gametocyte density at the time of mosquito feeding 
(AOR=8.33; 95%CI 3.91-17.78 and AOR=6.58; 95%CI 4.16-10.40  for 10-fold increases in gametocyte 
density, respectively) and significantly decreased following PQ treatment (Table 3).  The reduction in 
odds of mosquito infectivity over time associated with PQ dose of 0.25mg/kg was significantly higher 
compared to lower doses (0.0625-0.125mg/kg) (ratio of AORs per day=17.84; 95%CI 4.93-64.52; 
p<0.001 for a participant infecting at least one mosquito and 10.36; 95%CI 4.67-22.98; p<0.001 for a 
mosquito becoming infected) and not statistically different from higher doses (0.4-0.5mg/kg) 
(p=0.433 and p=0.070, respectively). With the exception of those treated with AL, the odds did not 
decrease significantly over time for any of the schizontocidal drugs.  A PQ dose of 0.25mg/kg 
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decreased the risk of infecting at least one mosquito practically to zero by day 3 (Figure 4 and 
Supplementary Figure 2). 
 
Risk of bias 
Methodological factors potentially contributing to the risk bias and attrition bias are presented in 
Supplementary Table 5. Measurement of gametocyte carriage using molecular methods is 
automated minimising the risk of observer bias; laboratory personnel performing molecular assays 
or dissecting mosquitoes were blinded in all studies. Sensitivity analyses showed that exclusion of 
any of the studies did not change the main conclusions of the analysis. The effect of PQ dose on 
gametocyte positivity was estimated as median AOR=0.69 (range 0.65–0.70) on Day 7 and 0.58 
(range 0.54-0.62) on day 14 for a 0.1mg/kg increase.   
The only eligible study for which data were not available for this meta-analysis [8] presented similar 
findings to results of this analysis. In this study, the addition of a single dose of 45mg of PQ to DP 
treatment was associated with increased clearance of gametocytes (measured by PCR) on day 7 and 
day 14.  In the PQ arm, of 24 patients with gametocytes on enrolment, 22 cleared gametocytaemia 
by day 7 and all by day 14, compared to 11 (day 7) and 16 (day 14) of the 22 patients in the DP only 
arm. In their membrane feeding experiments, no mosquito infections occurred in the PQ arm one- 
and two-weeks post-treatment, while in the no-PQ arm 6.9% of feeding mosquitoes were infected 
on day 7 and 5.0% on day 14. 
 
Discussion 
This IPD-meta analysis estimated the effect of PQ as a single dose (ranging from 0.0625 to 
0.75mg/kg) on the transmission potential of falciparum malaria infections, when co-administered 
with schizonticidal drugs. Our findings confirm the gametocyte clearing and sterilizing effects of 
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single dose PQ and indicate that both the PQ and the schizonticidal partner drug are important 
determinants of gametocyte clearance and transmission potential. Regardless of the schizonticidal 
partner-drug, mosquito infections were rarely present one week after administration of PQ, 
however, only three of the fourteen studies contributed data to this analysis. 
Among currently licensed antimalarials for P. falciparum, PQ is unique in its ability to clear mature 
gametocytes persisting after ACT treatment. Since the impact of ACTs is largely restricted to 
immature, developing gametocytes [17], only a small proportion of infections develop gametocytes 
after ACTs whilst gametocytes that are present prior to treatment may persist [6]. In the current 
analysis, more than 20% of individuals who were gametocyte-negative at enrolment became 
gametocyte positive by molecular gametocyte detection methods shortly after treatment. Given 
that gametocytes first appear 8.5-12 days after their asexual progenitors [18] and transcripts specific 
to mature gametocytes are first observed on day 3 based on the current data, it is likely that this 
reflects density fluctuations of mature gametocytes already present prior to treatment [19], rather 
than de novo gametocyte production. In line with this, PQ administration prior to first detection of 
gametocytes reduced the proportion of patients with gametocytes during follow-up.  
Gametocyte kinetics in patients who presented with peripheral gametocytaemia were strongly 
dependent on the schizontocidal treatment administered. Non-ACTs leave gametocytes largely 
unaffected, with gametocyte kinetics resembling a natural decay, while ACTs are only effective 
against early gametocytes [2, 20]. Also, ACTs differ markedly in their impact on gametocyte carriage 
[6, 7, 21], potentially due to the effects of the non-artemisinin partner drugs. Whilst lumefantrine 
affects gametocytes and their infectivity [22] piperaquine has limited effect on either developing or 
mature gametocytes [23]. Furthermore, the artemisinin derivative dose recommended by the 
manufacturer is significantly higher for AL than for DP. In the current pooled analysis, individuals 
receiving AL were considerably less likely to have patent gametocytaemia on day 14 compared to DP 
(AOR 0.18; 95% CI 0.08-0.44) and considerably less likely to infect mosquitoes. The addition of PQ 
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significantly reduced gametocyte carriage in all treatment groups [24] and did so in a dose-
dependent manner [25]. When given in combination with AL, the 0.25mg/kg, the WHO-
recommended dose, reduced gametocyte prevalence 7 days after treatment initiation to 22%, and 
this reduction is similar to that observed for higher PQ doses (16%, p=0.202). For individuals 
receiving DP, the average gametocyte prevalence reduction for 0.25mg/kg PQ was only to 39% on 
day 7 post-treatment but higher PQ doses accelerated gametocyte clearance (to 15%, p=0.002), and 
a 0.40mg/kg primaquine dose co-administered with DP achieves a similar effect to a 0.25mg/kg dose 
co-administered with AL.  
However, gametocyte sterilization may precede gametocyte clearance [26, 27]. In three studies 
included where mosquito infection was used as an endpoint, the effect of PQ on preventing 
mosquito infection was apparent before gametocytes were fully cleared. Whilst the gametocyte 
clearing effect of PQ only became apparent on day 7  post-initiation of treatment, mosquito 
infections were already very rare on day 3 following treatment with 0.25mg/kg PQ. PQ doses below 
0.25mg/kg were associated with higher mosquito infection rates on day 3 whilst doses higher than 
0.25mg/kg did not augment or accelerate the transmission-blocking properties of PQ.  
Use scenarios for single-dose PQ include elimination settings and areas threatened by drug 
resistance [10]. The findings from this meta-analysis, of increased gametocyte clearance and near 
absence of mosquito infections after administration (only 10/220 individuals who received at least 
0.25mg/kg PQ infected mosquitoes in feeding assays), support PQ deployment in these scenarios. 
PQ has been co-administered with schizonticides in community-wide treatment campaigns [9, 28, 
29], on the assumption that asymptomatic infections constitute a substantial proportion of the 
human infectious reservoir for malaria in low-endemic settings [30, 31]. However, concerns have 
been raised regarding the risk:benefit ratio in these settings. A proportion of these populations are 
likely to be G6PD deficient with a concern that they may be at an increased risk of PQ-induced 
hemolysis.  However, the WHO-recommended single low dose of PQ has shown no significant risk in 
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recent studies specifically designed to assess safety in this population [14, 15], nor in recent studies 
primarily designed to determine PQ efficacy [32-34]. Results of an IPD meta-analysis of all available 
safety data will be published separately (PROSPERO CRD42019128185).   
While CYP2D6 activity is essential for the generation of metabolites implicated in hypnozoite-
clearance in P. vivax [35, 36], less is known about its potential impact  on gametocytocidal or 
transmission-blocking properties of PQ. Whilst PQ’s gametocytocidal activity may in part be 
unrelated to cytochrome CYP2D6 activity [36], gametocytes may persist longer after PQ treatment in 
individuals with low-moderate CYP2D6 activity [37]. A shortcoming of our meta-analysis is that we 
could not incorporate these possible effects of CYP2D6 metabolizer status on post-PQ gametocyte 
carriage or transmission. In general, the added value of gametocytocidal drugs in community 
treatment campaigns continues to be a matter of debate. Mathematical simulations indicate that 
the fraction of the asymptomatic population that is successfully treated with ACTs is considerably 
more important for the impact of treatment campaigns than the addition of PQ to ACTs  and that 
impact will depend on transmission intensity [38-40]. 
This study also highlights SPAQ’s poor ability to clear gametocytes with a considerably higher 
gametocyte prevalence on day 7 post initiation of treatment compared to DP or AL [41]. Seasonal 
malaria chemoprevention (SMC) using SPAQ is widely deployed across the Sahel region of Africa to 
reduce malaria morbidity in children under the age of 5 years old and consists of giving all children 
SPAQ 3 to 4 times monthly during the transmission season. In scenarios where SMC campaigns are 
considered in wider age groups, SMC may impact gametocyte carriage [42] and malaria transmission 
. For such scenarios, our findings suggest that either adding single low dose PQ to SPAQ or changing 
to an artemisinin-based combination of drugs may increase SMC impact [3]. 
Conclusions 
Our analysis, based on individual patient data from clinical trials that were primarily conducted in 
Africa, supports the use of PQ as a potent gametocytocide and transmission blocking tool for P. 
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falciparum malaria. Gametocyte-carriage and transmission after PQ treatment depend on the 
schizonticidal drug that PQ is combined with, and PQ doses higher than 0.25mg/kg may accelerate 
gametocyte clearance. However, this WHO-recommended dose effectively achieves near-complete 
reductions in mosquito infections regardless of ACT. Additional clinical trials are necessary to 
quantify the effect of PQ use at community level; that is, to determine whether the effect of PQ 
observed in mosquito feeding assays leads to detectable changes in community-wide transmission 
levels when the drug is systematically used in clusters of transmission.  
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Figures 
Figure 1. Forest plots of difference in proportions of participants with gametocytes (risk difference; 
RD) on each day of follow-up.  Only individuals with gametocytes at enrolment were included.  Day 
3:  Heterogeneity Χ2=14.90 (d.f.=8)  p=0.061; I-squared=46.3; Day 7: Heterogeneity Χ2=45.75 (d.f.=8) 
p<0.001; I-squared=82.5%; Day 14: Heterogeneity Χ2=70.21 (d.f.=8) p<0.001; I-squared=88.6%. 
Studies were excluded if no data was collected on a specific day, except for study 9 that did not 
include a PQ- arm (all days), and study 15 (day 3) in which PQ was administered on day 3 
.  
Figure 2. Predicted relationship between probability of gametocyte carriage on days 7 (left panel) 
and 14 (right panel) post treatment initiation and PQ dose. The dashed line represents this 
relationship for individuals treated with AL, and the solid line, for individuals treated with DP. 
Shaded areas correspond to 95% confidence intervals. Median values for other variables were 
assumed. 
Figure 3. Results of membrane feeding experiments on different days of follow-up, in relation to 
starting treatment (left panels) and time of PQ administration (right panels).  Whiskers represent 
95% CI adjusted for clustering (within patients in upper panels and within feeding experiments in 
lower panels). Red boxes represent data for PQ arms and blue boxes for arms without PQ 
administration. This figure includes all data combined from AL, DP and SPAQ treatment arms. 
Figure 4. Predicted risk of infecting at least one mosquito in the membrane feeding experiment, 
after administration of 0.25mg/kg dose of PQ (red line) or without PQ administration (blue line).  
Gametocytaemia of 100 gametocytes per microliter was assumed at the time of sampling. Results 
are presented for patients treated with AL (left panel) or DP (right panel). 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Table 1. Baseline characteristics of analysis population1.  AL, artemether-lumefantrine; ASSP, artesunate and suphadoxine-pyrimethamine; DP, 
dihydroartemisinin-piperaquine; PPQ, piperaquine; SPAQ, sulfadoxine-pyrimethamine and amodiaquine. 
Baseline Characteristics 
Primaquine No Primaquine All 
N Median[Range] or  n[%] N Median[Range] or  n[%] N Median[Range] or   n[%] 
Age (years) 1711 9 [0.5 - 84] 852 9 [1 - 84] 2563 9 [0.5 - 84] 
Age :                        
                                       < 5 years 1711 342 [20] 852 162 [19] 2563 504 [20] 
5-11 years 1711 799 [47] 852 376 [44] 2563 1175 [46] 
12+ years 1711 570 [33] 852 314 [37] 2563 884 [34] 
Sex: male 1598 901 [56] 835 472 [57] 2433 1373 [56] 
Weight-for-age score (waz) 328 -.7 [-3.5 - 2.6] 156 -.6 [-3.8 - 2.5] 484 -.7 [-3.8 - 2.6] 
Underweight (waz <-2) 328 38 [12] 156 21 [13] 484 59 [12] 
Temperature (C) 1188 36.5 [34.2 - 40.3] 653 36.7 [34.3 - 40.4] 1841 36.6 [34.2 - 40.4] 
Fever (>37.5C) 1207 120 [10] 653 119 [18] 1860 239 [13] 
Haemoglobin  (g/dL) 1688 11.7 [6 - 18.7] 837 11.7 [6.8 - 17.8] 2525 11.7 [6 - 18.7] 
Anemia (Hb<10 g/dL) 1688 240 [14] 837 126 [15] 2525 366 [14] 
Parasitaemia (/µL) 1618 560 [0 - 518180] 774 1000 [0 - 432000] 2392 687.5 [0 - 518180] 
Hyperparasitaemia ( >105/µL) 1618 103 [6] 774 36 [5] 2392 139 [6] 
Presence of gametocytes:                                       
Microscope 833 212 [25] 491 162 [33] 1324 375 [28] 
QT-Nasba 1215 925 [76] 501 385 [77] 1716 1310 [76] 
RT-PCR 525 408 [76] 410 407 [75] 945 715 [76] 
Gametocytaemia (/µL):                           
Microscope 132 64 [12 - 1136] 133 43 [16 - 3000] 265 48 [12 - 3000] 
QT-Nasba 871 22.7 [0 - 32733.6] 376 32.1 [0 - 17944.5] 1247 25.7 [0 - 32733.6] 
RT-PCR 249 29.6 [0 – 4988.8] 172 31.7 [0 - 6529.5] 421 30.5 [0 – 6529.5] 
G6PD:  Deficient 1581 96 [6] 743 49 [7] 2324 145 [6] 
Treatment Administered  
Schizontal treatment:                                     
AL 1718 858 [50] 856 420 [49] 2574 1278 [50] 
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article/doi/10.1093/infdis/jiaa498/5890806 by guest on 17 August 2020
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
ASSP 1718 106 [6] 856 106 [12] 2574 212 [8] 
DP 1718 734 [43] 856 310[36]* 2574 1044 [41]1 
SPAQ 1718 20 [1] 856 20 [2] 2574 40 [2] 
Dose of primaquine (mg/kg):                         
0.0625 1718 16 [1] 
    0.100 1718 115 [7] 
    0.125 1718 25 [1] 
    0.200 1718 172 [10] 
    0.250 1718 477 [28] 
    0.400 1718 474 [28] 
    0.500 1718 17 [1] 
    0.750 1718 422 [25] 
     
1Includes 20 patients who received DP and Methylene Blue and only contributed baseline data from membrane feeding experiments 
 
 
1estimates also adjusted for study included as a covariate   
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Table 2. Multivariable mixed effects logistic regression for gametocyte positivity1 on days 7 and 14 in patients with detectable gametocytaemia on day 0.  
AOR, adjusted odds ratio. N= number of patients included in the model, n = number of patients with positive outcome. 
 Day 7 gametocyte positivity 
N=1,509 , n=546 
Day 14 gametocyte positivity 
N=1,316  n=306 
Parameter 
PQ dose (per 0.1mg/kg) 
Log10 gametocytaemia2 
AOR 
0.69 
1.85  
95% CI 
0.65-0.74 
1.61 -2.13 
P-value 
<0.001 
<0.001 
AOR 
0.58  
1.87 
95% CI 
0.53-0.64 
1.56-2.25 
P-value 
<0.001 
<0.001 
Hyperparasitaemia(>105 parasites/µL) 
Haemoglobin (g/dL) 
Treatment 
                     DP 
                    AL 
                   ASSP 
                   SPAQ 
0.28 
0.85 
 
Reference 
0.50 
1.20 
16.16 
0.15-0.53 
0.78-0.92 
 
 
0.28-0.90 
0.45-3.21 
1.88 -138.70 
<0.001 
<0.001 
 
 
0.021 
0.723 
0.011 
 
 
 
Reference 
0.18 
0.99 
1.30 
 
 
 
 
0.08-0.44 
0.26-3.80 
0.30 – 5.72 
 
 
 
 
<0.001 
0.983 
0.726 
       
1 When results from both molecular methods were available, gametocyte density was defined by qRT-PCR. 
2 In studies where only gametocyte positivity was determined by a molecular method, density measures by microscopy were included. For patients with 
positive samples by molecular method and zero microscopy count (n =230 on Day 7 and n= 180 on Day 14), density was assumed to be  8 (half of the 
detection limit by microscopy assuming microscopic quantification against 500 white blood cells or 1/16th of a microliter).   
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Table 3. Multivariable mixed effects logistic regression for A) probability of a patient infecting at least one mosquito B) probability of a mosquito being 
infected  in membrane experiments conducted on blood taken within 14 days from treatment in patients with gametocytaemia at baseline and at the time 
of sampling. AOR, adjusted odds ratio.  
 A. Patient infecting at least 1  mosquito 
N=317 patients , n=684 feeds 
B. Mosquito gets infected 
N=41,840 mosquitoes  n=664 feeds, 317 patients 
Parameter 
Effect of PQ dose over time (per day)                                             
0.0625-0.125 mg/kg 
0.25mg/kg 
0.4-0.5 mg/kg 
Effect of treatment over time (per 
day) 
AL      
DP 
SPAQ 
 
Log10 gametocytaemia 
at the time of sampling 
AOR1 
 
0.50 
0.03 
0.06 
 
0.56 
0.84 
0.97 
 
8.33 
95% CI 
0.31-0.81 
0.01 – 0.11 
0.01 – 0.32 
 
0.36-0.87 
0.69-1.02 
0.76-1.23 
 
3.91 -17.78 
 
P-value 
 
0.004 
<0.001 
0.001 
 
0.010 
0.082 
0.798 
 
<0.001 
 
AOR1 
 
0.57 
0.05 
0.18 
 
0.52 
0.96 
0.98 
 
6.58 
95% CI 
 
0.41-0.70 
0.03-0.12 
0.06-0.54 
 
0.37-0.73 
0.83-1.11 
0.83-1.16 
 
4.16-10.40 
 
P-value 
 
0.001 
<0.001 
0.002 
 
<0.001 
0.593 
0.807 
 
<0.001 
       
1estimates also adjusted for study included as a covariate   
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